Pharming announces first patient enrolled in leniolisib trial

Pharming announced that the first patient has been enrolled in its Phase III clinical trial evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta, or PI3Kd, inhibitor, in children with activated phosphoinositide 3-kinase delta syndrome, or APDS. There is currently no approved treatment for this complex and progressive disease caused by genetic variants.